Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS628
- Development stage
- Phase 3
- Lead developer
- Zhejiang Hisun Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
HS628 is a tocilizumab biosimilar developed by Zhejiang Hisun Pharmaceutical. It is a recombinant humanized monoclonal antibody that functions as an interleukin-6 receptor alpha subunit (IL-6RA) antagonist. By binding specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), HS628 inhibits IL-6-mediated pro-inflammatory signaling, which is a key driver in the pathogenesis of various autoimmune and inflammatory diseases. The drug is primarily being evaluated in Phase III clinical trials for the treatment of moderate to severe active rheumatoid arthritis in patients who have had an inadequate response to methotrexate. Additionally, it is being developed for other indications including cytokine release syndrome and systemic onset juvenile chronic arthritis.
- Brand names
- ActemraTyenneAvtozmaTofidenceRoactemra
- Other names
- tocilizumab biosimilar
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IL-6R (Interleukin-6 receptor subunit alpha)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on HS628.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS628.